RxDoctor Payments DataLook up a doctor →

Madar Abed, MD

Cardiovascular Disease · Flushing, MINPI 1235165275

Payments from drug & device makers

$236,743in general payments, 2019–2025

Across 632 payments — averaging $374.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$128K
  • Medtronic$77K
  • Abbott$16K
  • Biotronik Inc.$9K
  • Atricure, Inc.$1K
  • Novartis$921
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$60,20060%
  • Travel & lodging$21,97122%
  • Food & beverage$17,70318%
  • Education$2460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$236,743 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$332,336
Medicare patients
464
Services billed
2,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$101,445
EntrestoSacubitril/Valsartan23$33,718
XareltoRivaroxaban30$32,567
Amiodarone Hcl52$1,686
Metoprolol Succinate69$854
Carvedilol38$491
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav66$369
Metoprolol Tartrate36$330
Atorvastatin Calcium21$328
Spironolactone27$264
Doxycycline Monohydrate16$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$101,445119 claims
NovartisEntresto$921$33,71823 claims
Johnson & JohnsonXarelto$269$32,56730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Flushing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →